Breast cancer remains the leading cause of death among women worldwide. Traditional chemotherapy is often limited by poor drug solubility, systemic toxicity, and nonspecific targeting, leading to significant side effects. Nanoparticle-based drug delivery systems offer promising alternatives to traditional chemotherapy, improving solubility and target specificity. This paper explores how nanoparticles could transform breast cancer therapy and its pathogenesis. The pathophysiological complexity of breast cancer, including genetic and molecular changes driving tumor development and metastases, presents novel approaches to these problems. Nanoparticle-based drug delivery methods offer two main approaches: active and passive targeting. Active targeting involves functionalizing nanoparticles with ligands or antibodies that bind to receptors overexpressed on cancer cells, improving drug delivery accuracy. Nanoparticle-based drug delivery methods offer benefits such as regulated and prolonged drug release, enhanced solubility and bioavailability of hydrophobic drugs, and reduced negative effects. Potential applications include liposomes, dendrimers, and polymeric nanoparticles in preclinical and clinical environments. However, challenges such as regulatory obstacles, potential toxicity, and mass production complexity hinder their clinical application. The study concludes with future projections indicating the potential for further innovation in drug delivery techniques to address issues with poorly soluble drugs.